BlackRock Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

BlackRock Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$13K	Sell	12,442 -167,534	-93%	-$191K	﹤0.01%	3533
2016 Q3	$196K	Sell	179,976 -121,751	-40%	-$110K	﹤0.01%	2708
2016 Q2	$214K	Sell	301,727 -32,034	-10%	-$25.8K	﹤0.01%	2567
2016 Q1	$391K	Buy	333,761 +2,941	+0.9%	+$4.56K	﹤0.01%	2212
2015 Q4	$811K	Sell	330,820 -16,991	-5%	-$48.7K	﹤0.01%	1823
2015 Q3	$1.04M	Buy	347,811 +123,180	+55%	+$532K	﹤0.01%	1661
2015 Q2	$928K	Buy	224,631 +214,754	+2,174%	+$856K	﹤0.01%	1718
2015 Q1	$43K	Hold	9,877	–	–	﹤0.01%	3285
2014 Q4	$29K	Buy	+9,877	New	+$27.1K	﹤0.01%	3405

Other funds holding CPRX

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

TCM

Tanaka Capital Management New York $59.9M AUM

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock Advisors's CPRX Position: Q4 2016 in Review

BlackRock Advisors reduced its Catalyst Pharmaceutical (CPRX) stake by 93% in Q4 2016, selling an estimated $191K and leaving 12,442 shares worth $13K. The position accounts for ﹤0.01% of the portfolio, ranked #3533.

BlackRock Advisors first reported a position in CPRX in Q4 2014 and has held it in 9 quarters since. The position peaked at $1.04M in Q3 2015. 54 funds tracked by Wall St. Rank hold CPRX as of Q4 2016.

BlackRock Advisors held 12,442 shares of Catalyst Pharmaceutical worth $13K as of Q4 2016.
BlackRock Advisors sold 167,534 Catalyst Pharmaceutical shares in Q4 2016, an estimated $191K.
Catalyst Pharmaceutical made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #3533 holding.
BlackRock Advisors first reported a position in Catalyst Pharmaceutical in Q4 2014 and has held it in 9 quarters since.
BlackRock Advisors's Catalyst Pharmaceutical position peaked at $1.04M in Q3 2015.
54 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.